Welcome to our dedicated page for Q32 BIO news (Ticker: QTTB), a resource for investors and traders seeking the latest updates and insights on Q32 BIO stock.
Q32 Bio Inc. (NASDAQ: QTTB) is a clinical-stage biotechnology company pioneering novel therapies for autoimmune and inflammatory diseases through targeted immune system modulation. This dedicated news hub provides investors and industry professionals with essential updates on the company's scientific advancements and corporate developments.
Access real-time announcements including clinical trial progress, regulatory milestones, and strategic initiatives. Our curated collection features press releases detailing Q32 Bio's lead candidates bempikibart and ADX-097, partnership announcements, and financial disclosures.
Key updates cover therapeutic program advancements in adaptive/innate immunity research, manufacturing collaborations, and intellectual property developments. Users gain centralized access to scientifically significant updates while maintaining compliance with financial disclosure standards.
Bookmark this page for streamlined tracking of Q32 Bio's progress in developing biologics that rebalance immune responses. Check regularly for authoritative updates directly from company sources and verified financial news outlets.
Q32 Bio (NASDAQ: QTTB) reported Q3 2024 financial results with $89.1 million in cash and cash equivalents as of September 30, 2024, expected to fund operations into mid-2026. The company anticipates topline results from two Phase 2 trials of bempikibart in atopic dermatitis and alopecia areata in December 2024. Q3 saw a net loss of $17.6 million, with R&D expenses increasing to $14.3 million from $7.5 million year-over-year. Enrollment continues in the ADX-097 Phase 2 basket trial for complement mediated renal diseases, with initial data expected in 1H'25 and topline results in 2H'25.
Q32 Bio (Nasdaq: QTTB), a clinical stage biotechnology company developing biologic therapeutics for immune homeostasis, has announced its upcoming participation in Guggenheim's Inaugural Healthcare Innovation Conference. The company's management will engage in a fireside chat on Tuesday, November 12, 2024, at 10:00 a.m. E.T. in Boston, MA. The presentation will be accessible via webcast on Q32 Bio's website, with replays available for 90 days after the event.
Q32 Bio Inc. (Nasdaq: QTTB) announced it will present clinical data for ADX-097, its lead product candidate from its tissue-targeted complement inhibitor platform, at the American Society of Nephrology (ASN) Kidney Week 2024. The presentation will highlight data from the completed first-in-human, Phase 1 ascending dose clinical trial of ADX-097 in healthy volunteers.
Key points:
- ADX-097 is a humanized anti-C3d mAb fusion protein being evaluated for renal diseases associated with increased complement activation.
- The Phase 1 trial showed ADX-097 to be generally well-tolerated with desirable pharmacokinetics and pharmacodynamics properties.
- Results support Phase 2 dose selection and continued clinical advancement of ADX-097.
- Q32 Bio aims to achieve relevant complement inhibition directly in the tissue while minimizing systemic activity.
- The company is currently advancing ADX-097 in two Phase 2 clinical trials.
Q32 Bio Inc. (Nasdaq: QTTB), a clinical stage biotechnology company, has announced its participation in three upcoming investor conferences in September 2024. The company, which focuses on developing biologic therapeutics to restore immune homeostasis, will be present at:
1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 5 in New York, NY
2. 2024 Cantor Fitzgerald Global Healthcare Conference on September 17 in New York, NY (presentation at 3:40 p.m. E.T.)
3. Stifel 2024 Virtual Immunology and Inflammation Summit on September 18 (virtual presentation at 11:30 a.m. E.T.)
Webcasts of the Cantor and Stifel presentations will be available on Q32 Bio's website, with archived replays accessible for 30 days after the events.
Q32 Bio (Nasdaq: QTTB) reported Q2 2024 financial results and provided corporate updates. Key highlights include:
1. Completed enrollment in bempikibart atopic dermatitis Phase 2 trial, increasing trial size to 121 patients.
2. Bempikibart Phase 2 topline results in atopic dermatitis and alopecia areata expected in Q4 2024.
3. Enrolling patients in ADX-097 Phase 2 basket trial for complement mediated renal diseases.
4. Cash position of $107.6 million as of June 30, 2024, expected to fund operations through four Phase 2 clinical milestones and into mid-2026.
5. Q2 2024 net loss of $17.0 million, or $1.42 per share, compared to $5.8 million, or $16.69 per share, in Q2 2023.
Q32 Bio announced the completion of patient enrollment for its SIGNAL-AD Phase 2 clinical trial of bempikibart for atopic dermatitis (AD). The trial surpassed its target, enrolling 121 patients due to high demand. Bempikibart is an anti-IL-7Rα antibody aimed at regulating immune function to combat AD. The trial consists of two parts: Part A for safety and dose selection, and Part B for efficacy and safety comparison with placebo. Topline results are expected in Q4 2024. This milestone follows the completion of another Phase 2 trial for alopecia areata (AA).
Q32 Bio (Nasdaq: QTTB), a clinical-stage biotechnology company, has joined the Russell 3000® Index as of July 1, 2024. The inclusion follows the 2024 annual reconstitution of Russell indexes, which tracks the 4,000 largest U.S. stocks by market capitalization. Q32 Bio’s addition reflects its ongoing progress in developing therapeutics for autoimmune and inflammatory diseases. This milestone is expected to help the company broaden its shareholder base and gain greater visibility among investment managers and institutional investors who use Russell indexes for benchmarking and index funds.
Q32 Bio Inc. (NASDAQ: QTTB) reported financial results for Q1 2024, completing enrollment in bempikibart AA Phase 2 clinical trial, on-track for AD Phase 2. ADX-097 progresses with trials set for 2024 and 2025. The company completed a reverse merger with Homology Medicines, raising $42 million. Cash reserves stand at $135.3 million, expected to last until mid-2026.
FAQ
What is the current stock price of Q32 BIO (QTTB)?
What is the market cap of Q32 BIO (QTTB)?
